**Supplementary materials**

**ESM Table 1**. A)-C) Odds ratios of remission, response and improvement at 24 vs. 12 weeks for pramipexole vs. ariripiprazole. D) Regression coefficients of functioning over time by type of augmentation. Results obtained from repeated measures generalized linear mixed models.

1. *Remission (HDRS ≤ 7)*

|  |  |  |
| --- | --- | --- |
|  | **OR (95%CI)** | **p-value** |
| Intercept | 0.18 (0.06; 0.54) | 0.002 |
| **Type of augmentation** |  |  |
| aripiprazole | r.c. |  |
| pramipexole | 4.24 (1.54; 11.67) | **0.005** |
| **Time** |  |  |
| 12-week | r.c. |  |
| 24-week | 1.67 (0.67; 4.15) | 0.265 |
| **Augmentation\*time** | 1.61 (0.53; 4.94) | 0.403 |
| **Propensity score** | 1.79 (0.57; 5.60) | 0.314 |
| Binomial distribution with a logit-link function.  OR: Odds ratio; r.c.: reference category;  95% CI: 95% Confidence Interval | | |

1. *Response (≥50% reduction in HDRS)*

|  |  |  |
| --- | --- | --- |
|  | **OR (95%CI)** | **p-value** |
| Intercept | 0.43 (0.16; 1.12) | 0.085 |
| **Type of augmentation** |  |  |
| aripiprazole | r.c. |  |
| pramipexole | 3.77 (1.48; 9.60) | **0.006** |
| **Time** |  |  |
| 12-week | r.c. |  |
| 24-week | 1.30 (0.57; 2.96) | 0.539 |
| **Augmentation\*time** | 1.39 (0.47; 4.06) | 0.550 |
| **Propensity score** | 1.30 (0.44; 3.83) | 0.633 |
| Binomial distribution with a logit-link function.  OR: Odds ratio; r.c.: reference category;  95% CI: 95% Confidence Interval | | |

1. *Improvement (CGI-i < 2)*

|  |  |  |
| --- | --- | --- |
|  | **OR (95%CI)** | **p-value** |
| Intercept | 1.79 (0.64; 5.02) | 0.268 |
| **Type of augmentation** |  |  |
| aripiprazole | r.c. |  |
| pramipexole | 2.76 (0.94; 8.10) | 0.064 |
| **Time** |  |  |
| 12-week | r.c. |  |
| 24-week | 0.81 (0.33; 2.01) | 0.648 |
| **Augmentation\*time** | 0.94 (0.27; 3.26) | 0.927 |
| **Propensity score** | 2.34 (0.69; 7.91) | 0.172 |
| Binomial distribution with a logit-link function.  OR: Odds ratio; r.c.: reference category;  95% CI: 95% Confidence Interval | | |

1. *GAF*

|  |  |  |
| --- | --- | --- |
|  | **b (95%CI)** | **p-value** |
| Intercept | 3.87 (3.81; 3.94) | **<0.001** |
| **Type of augmentation** |  |  |
| Aripiprazole | r.c. |  |
| Pramipexole | 0.09 (0.03; 0.15) | **0.003** |
| **Time** |  |  |
| Baseline | r.c. |  |
| 12-week | 0.16 (0.09; 0.22) | **<0.001** |
| 24-week | 0.19 (0.12; 0.25) | **<0.001** |
| **Augmentation\*time** |  |  |
| aripiprazole\*12-week | 0.10 (0.02; 0.19) | **0.014** |
| aripiprazole\*24-week | 0.13 (0.04; 0.21) | **0.004** |
| **Propensity score** | 0.13 (0.06; 0.20) | **<0.001** |
| Gamma distribution with a log-link function.  b: beta coefficient; r.c.: reference category;  95% CI: 95% Confidence Interval | | |

**ESM Table 2.** Predicted rates of remission, response, improvement and predicted mean of GAF score according to type of augmentation and time, adjusted for the propensity score. Results obtained from repeated measures generalized linear mixed models.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Baseline** | **12-week** | **24-week** |
| **Remission, estimated rate (*95% CI*)** |  |  |  |
| Pramipexole |  | 49.7% | 72.7% |
| (*37.7% - 60.9%*) | (*61.8% - 82.0%*) |
| Aripiprazole |  | 18.9% | 28.1% |
| (*9.6% - 33.7%*) | (*16.0% - 44.3%*) |
| **Response, estimated rate (*95% CI*)** |  |  |  |
| Pramipexole |  | 64.1% | 76.2% |
| (*51.9% - 74.8%*) | (*64.8% - 84.8%*) |
| Aripiprazole |  | 32.2% | 38.0% |
| (*19.3% - 48.5%*) | (*23.9% - 54.5%*) |
| **Improvement, estimated rate (*95% CI*)** |  |  |  |
| Pramipexole |  | 87.2% | 83.9% |
| (*77.8% - 93.0%*) | (*73.6% - 90.7%*) |
| Aripiprazole |  | 71.2% | 66.7% |
| (*54.3% - 83.8%*) | (*49.4% - 80.4%*) |
| **GAF, estimated mean (*95% CI*)** |  |  |  |
| Pramipexole | 55.5 | 71.9 | 75.7 |
| (*53.6 - 57.4*) | (*68.9 - 75.1*) | (*72.5 - 79.1*) |
| Aripiprazole | 50.6 | 59.1 | 60.8 |
| (*48.3 - 52.9*) | (*55.9 - 62.4*) | (*57.4 - 64.4*) |